VivoSense, Inc. has joined the Clinical Trials Transformation Initiative (CTTI) to advance the efficiency and efficacy of clinical trial research and care. As a leading provider of digital endpoint solutions derived from wearable sensors, VivoSense will contribute to CTTI's foundational efforts to improve quality, patient engagement, novel trial design, digital health trials, investigator, and site support and ethics in research.
CTTI convenes its 80+ members and 500+ multi-stakeholder organizations and individuals from across the clinical trials enterprise to discuss issues, exchange ideas, and bring innovative solutions to the greatest challenges in clinical research. VivoSense is committed to CTTI’s mission to build better, faster clinical trials. These efforts are reinforced by CTTI’s Transforming Trials 2030 vision centering on five principles:
- That clinical trials in 2030 be patient-centered and easily accessible
- Fully integrated into health processes
- Designed with a quality approach
- Maximally leverage all available data
- And improve population health.
“The VivoSense team looks forward to working with CTTI and their member organizations. Our mission is closely aligned with CTTI efforts. Both organizations are passionate about increasing the efficiency and efficacy of clinical trials to improve patient care.”
~ Kate Lyden, VivoSense Chief Science officer and CTTI Steering Committee member
VivoSense, Inc., is an agile end-to-end scientific solutions company developing novel digital endpoints from wearable sensor data. We are focused on healthcare clinical trial research & care. VivoSense’s hypothesis-driven framework provides analytical and clinical validation leading to FDA approval. The proprietary VivoSense® software enables the creation and validation of novel digital biomarkers from wearable sensor data, which constitute primary and secondary clinical endpoints in regulated international pharmaceutical trials.